Zepatier lands co-exclusive status on Express Scripts 2019 formulary

Express Scripts Holding Co. (NASDAQ:ESRX) announced its 2019 National Preferred Formulary Exclusions, noting that the exclusions were driven not only by the size of the rebate as in years past, but also by lower list prices, garnering HCV drug Zepatier grazoprevir/elbasvir co-exclusive status.

The PBM noted that in some instances, where the agents were deemed clinically equivalent, it selected those with the lowest list price, including HIV therapies Symfi efavirenz/lamivudine/tenofovir and Symfi Lo, which have 40% lower list prices than Atripla emtricitabine/tenofovir/efavirenz. Mylan N.V. (NASDAQ:MYL) markets both Symfi drugs and Gilead Sciences Inc. (NASDAQ:GILD) markets Atripla...